Chad Cochran, DO
Sports Medicine · Youngstown, OHNPI 1639600695
Payments from drug & device makers
Across 48 payments — averaging $23.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$169
- Johnson & Johnson$167
- Biohaven Pharmaceutical Holding Company Ltd.$133
- AstraZeneca$123
- Teva Pharmaceuticals USA, Inc.$100
- AbbVie$46
- plus $378 from 18 others
What the payments were for
- Food & beverage$1,115100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 8 | $169 |
| Johnson & Johnson(3 entities) | 8 | $167 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $133 |
| AstraZeneca | 3 | $123 |
| Teva Pharmaceuticals USA, Inc. | 1 | $100 |
| AbbVie | 3 | $46 |
| Novo Nordisk | 3 | $38 |
| DJO, LLC | 1 | $37 |
| Novartis | 2 | $31 |
| Nabriva Therapeutics, PLC | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Bioventus LLC | 1 | $19 |
| Si-bone, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Globus Medical | 1 | $13 |
| Abbott | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$123
How this compares
$1,115 in reported general payments places this provider in the 45th percentile of 278 sports medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 44 | $70 |
| Tramadol Hcl | 12 | $70 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 11 | $36 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Youngstown
- David FlaniganColumbus$1.7M
- Robert HeidtCincinnati$911K
- Thomas EllisDublin$427K
- Paul SaluanCleveland$367K
- Vincent SammarcoCincinnati$361K
- Jovan LaskovskiAkron$337K
- Julie BishopColumbus$322K
- Brian GraweCincinnati$293K
- Kurt SpindlerGarfiled Heights$272K
- Mark SchickendantzCleveland$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.